quinidine gluconate structure
|
Common Name | quinidine gluconate | ||
---|---|---|---|---|
CAS Number | 7054-25-3 | Molecular Weight | 520.57200 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C26H36N2O9 | Melting Point | 175-176ºC | |
MSDS | Chinese USA | Flash Point | N/A | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of quinidine gluconateQuinate is an antiarrhythmic agent. Quinate is a potent, orally active, selective cytochrome P450db inhibitor. Quinate is also a K+ channel blocker with an IC50 of 19.9 μM. Quinate can be used for malaria research[1][2][3]. |
Name | quinidine D-gluconate |
---|---|
Synonym | More Synonyms |
Description | Quinate is an antiarrhythmic agent. Quinate is a potent, orally active, selective cytochrome P450db inhibitor. Quinate is also a K+ channel blocker with an IC50 of 19.9 μM. Quinate can be used for malaria research[1][2][3]. |
---|---|
Related Catalog | |
In Vitro | Quinidine is an anti-arrythmic drug which affects ionic currents in heart muscle and which has also been shown to be a potent blocker of several classes of K+ channel in a variety of cell types[1]. Bath application of quinidine causes a dose-dependent reduction of the peak amplitude of Ik. The Kd for blockade of Ik at 0 mV is estimated to be 41 μM[1]. Quinidine elicits a dose-dependent increase of the rate of the decay of Ik and this effect is enhanced by membrane depolarization. Quinidine also causes a 5 mV hyperpolarizing shift of the steady-state inactivation curve and increases the half-time for recovery from inactivation. Quinidine does not affect the onset of inactivation measured at -30 mV[1]. |
In Vivo | Quinidine sulfate is rapidly absorbed, with peak plasma concentrations 60-90 min after an oral dose. Other salts (gluconate, polygalacturonate) are more slowly absorbed, with lower peak concentrations[2]. Quinidine is approximately 70-90 % bound to plasma proteins. It undergoes hepatic oxidative metabolism to form an N-oxide, a 3-hydroxy form, an O-demethyl form and 2'-quinidinone[2]. Quinidine inhibits metabolism of amphetamine in rats. Quinidine pretreatment results in a significant decrease in the excretion of p-hydroxyamphetamine at 24 and 48 h to 7.2 and 24.1% of the vehicle-control levels, respectively, accompanied by a significant increase in amphetamine excretion between 24 and 48 h to 542% of the control[3]. |
References |
Melting Point | 175-176ºC |
---|---|
Molecular Formula | C26H36N2O9 |
Molecular Weight | 520.57200 |
Exact Mass | 520.24200 |
PSA | 184.04000 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 + H312 + H332 |
Precautionary Statements | P261-P280-P301 + P312 + P330 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xn,Xi |
Risk Phrases | 20/21/22-36/37/38 |
Safety Phrases | 36-26 |
RIDADR | UN 1544 |
RTECS | LZ5250000 |
Packaging Group | III |
Hazard Class | 6.1(b) |
Disposition of 3-hydroxyquinidine in patients receiving initial intravenous quinidine gluconate for electrophysiology testing of ventricular tachycardia.
DICP 23(5) , 375-8, (1989) The formation rate constant and elimination rate constant for 3-hydroxyquinidine were determined in eight patients with ventricular tachycardia. These two parameters (mean +/- SD) were found to be 0.7... |
|
Quinidine-induced rheumatic syndromes.
Semin. Arthritis Rheum. 24(5) , 315-22, (1995) Quinidine is a commonly used antiarrhythmic agent that is rarely associated with rheumatologic toxicity. However, quinidine-induced lupus, antinuclear antibody negative lupus-like syndrome, polymyalgi... |
|
Transfusion-transmitted malaria in a kidney transplant recipient. How safe is our blood transfusion?
Saudi Med. J. 29(2) , 293-5, (2008) A 51-year-old male patient with living, unrelated kidney transplantation in Iran in June 2001, developed Plasmodium falciparum P. falciparum infection. He was maintained on cyclosporine A, mycophenola... |
quinidine gluconate |